vs

Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP (NEN). Click either name above to swap in a different company.

ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $23.6M, roughly 1.6× NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP). ImmunityBio, Inc. runs the higher net margin — -161.8% vs -677.3%, a 515.5% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 15.7%).

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

New England Realty Associates Limited Partnership is a real estate investment entity that owns, operates and manages residential and commercial properties primarily across the U.S. New England region. Its core assets include multifamily apartments, mixed-use properties and small commercial spaces, serving tenants across Massachusetts, New Hampshire and adjacent states, delivering steady returns to unitholders via rental income and property value growth.

IBRX vs NEN — Head-to-Head

Bigger by revenue
IBRX
IBRX
1.6× larger
IBRX
$38.3M
$23.6M
NEN
Growing faster (revenue YoY)
IBRX
IBRX
+391.2% gap
IBRX
407.0%
15.7%
NEN
Higher net margin
IBRX
IBRX
515.5% more per $
IBRX
-161.8%
-677.3%
NEN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IBRX
IBRX
NEN
NEN
Revenue
$38.3M
$23.6M
Net Profit
$-61.9M
$-1.4M
Gross Margin
99.0%
Operating Margin
-169.0%
14.0%
Net Margin
-161.8%
-677.3%
Revenue YoY
407.0%
15.7%
Net Profit YoY
-4.7%
-133.0%
EPS (diluted)
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBRX
IBRX
NEN
NEN
Q4 25
$38.3M
$23.6M
Q3 25
$32.1M
$23.7M
Q2 25
$26.4M
$21.2M
Q1 25
$16.5M
$20.7M
Q4 24
$7.6M
$20.4M
Q3 24
$6.1M
$20.2M
Q2 24
$20.1M
Q1 24
$19.9M
Net Profit
IBRX
IBRX
NEN
NEN
Q4 25
$-61.9M
$-1.4M
Q3 25
$-67.3M
$-521.8K
Q2 25
$-92.6M
$4.1M
Q1 25
$-129.6M
$3.8M
Q4 24
$-59.2M
$4.2M
Q3 24
$-85.7M
$3.9M
Q2 24
$4.1M
Q1 24
$3.5M
Gross Margin
IBRX
IBRX
NEN
NEN
Q4 25
99.0%
Q3 25
99.4%
Q2 25
99.5%
Q1 25
99.6%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
IBRX
IBRX
NEN
NEN
Q4 25
-169.0%
14.0%
Q3 25
-173.5%
20.0%
Q2 25
-269.8%
33.3%
Q1 25
-390.1%
30.1%
Q4 24
-919.0%
32.4%
Q3 24
-1314.3%
32.0%
Q2 24
32.6%
Q1 24
28.9%
Net Margin
IBRX
IBRX
NEN
NEN
Q4 25
-161.8%
-677.3%
Q3 25
-209.8%
-2.2%
Q2 25
-350.3%
19.5%
Q1 25
-784.9%
18.3%
Q4 24
-783.4%
20.7%
Q3 24
-1404.0%
19.3%
Q2 24
20.3%
Q1 24
17.4%
EPS (diluted)
IBRX
IBRX
NEN
NEN
Q4 25
$-0.06
Q3 25
$-0.07
Q2 25
$-0.10
Q1 25
$-0.15
Q4 24
$-0.08
Q3 24
$-0.14
Q2 24
Q1 24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBRX
IBRX
NEN
NEN
Cash + ST InvestmentsLiquidity on hand
$242.8M
$26.7M
Total DebtLower is stronger
$531.0M
Stockholders' EquityBook value
$-500.5M
Total Assets
$501.9M
$505.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBRX
IBRX
NEN
NEN
Q4 25
$242.8M
$26.7M
Q3 25
$257.8M
$13.4M
Q2 25
$153.7M
$16.7M
Q1 25
$61.6M
$30.9M
Q4 24
$149.8M
$17.6M
Q3 24
$130.4M
$15.1M
Q2 24
$13.5M
Q1 24
$28.8M
Total Debt
IBRX
IBRX
NEN
NEN
Q4 25
$531.0M
Q3 25
$514.2M
Q2 25
$514.3M
Q1 25
$407.8M
Q4 24
$408.6M
Q3 24
$409.3M
Q2 24
$410.0M
Q1 24
$410.7M
Stockholders' Equity
IBRX
IBRX
NEN
NEN
Q4 25
$-500.5M
Q3 25
$-524.3M
Q2 25
$-570.7M
Q1 25
$-591.4M
Q4 24
$-489.1M
Q3 24
$-745.1M
Q2 24
Q1 24
Total Assets
IBRX
IBRX
NEN
NEN
Q4 25
$501.9M
$505.3M
Q3 25
$519.0M
$492.9M
Q2 25
$402.1M
$494.8M
Q1 25
$303.8M
$385.2M
Q4 24
$382.9M
$393.5M
Q3 24
$364.6M
$387.4M
Q2 24
$383.7M
Q1 24
$381.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBRX
IBRX
NEN
NEN
Operating Cash FlowLast quarter
$-70.4M
$27.7M
Free Cash FlowOCF − Capex
$-71.3M
FCF MarginFCF / Revenue
-186.2%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBRX
IBRX
NEN
NEN
Q4 25
$-70.4M
$27.7M
Q3 25
$-68.9M
$2.3M
Q2 25
$-79.7M
$12.5M
Q1 25
$-85.9M
$5.5M
Q4 24
$-85.1M
$31.9M
Q3 24
$-98.8M
$8.5M
Q2 24
$5.4M
Q1 24
$6.1M
Free Cash Flow
IBRX
IBRX
NEN
NEN
Q4 25
$-71.3M
Q3 25
$-69.6M
Q2 25
$-80.8M
Q1 25
$-87.0M
Q4 24
$-87.3M
Q3 24
$-101.6M
Q2 24
Q1 24
FCF Margin
IBRX
IBRX
NEN
NEN
Q4 25
-186.2%
Q3 25
-217.2%
Q2 25
-305.9%
Q1 25
-526.9%
Q4 24
-1155.4%
Q3 24
-1663.2%
Q2 24
Q1 24
Capex Intensity
IBRX
IBRX
NEN
NEN
Q4 25
2.4%
Q3 25
2.3%
Q2 25
4.1%
Q1 25
6.8%
Q4 24
28.0%
Q3 24
45.7%
Q2 24
Q1 24
Cash Conversion
IBRX
IBRX
NEN
NEN
Q4 25
Q3 25
Q2 25
3.02×
Q1 25
1.44×
Q4 24
7.57×
Q3 24
2.17×
Q2 24
1.32×
Q1 24
1.77×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons